NCT00787371View on ClinicalTrials.gov

Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Hepatitis C, ChronicHepatitis C
Interventions
BIOLOGICAL

PegIntron (peginterferon alfa-2b)

PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks

BIOLOGICAL

PegIntron (peginterferon alfa-2b)

PegIntron 0.5 mcg/kg SC QW for 12 weeks

BIOLOGICAL

PegIntron (peginterferon alfa-2b)

PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00787371 - Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED) | Biotech Hunter | Biotech Hunter